» Articles » PMID: 28547925

The Saponin D39 Blocks Dissociation of Non-muscular Myosin Heavy Chain IIA from TNF Receptor 2, Suppressing Tissue Factor Expression and Venous Thrombosis

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2017 May 27
PMID 28547925
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Non-muscular myosin heavy chain IIA (NMMHC IIA) plays a key role in tissue factor expression and venous thrombosis. Natural products might inhibit thrombosis through effects on NMMHC IIA. Here, we have shown that a natural saponin, D39, from Liriope muscari exerted anti-thrombotic activity in vivo, by targeting NMMHC IIA.

Experimental Approach: Expression and activity of tissue factor in endothelial cells were analysed in vitro by Western blot and simplified chromogenic assays. Interactions between D39 and NMMHC IIA were assessed by serial affinity chromatography and molecular docking analysis. D39-dependent interactions between NMMHC IIA and TNF receptor 2 (TNFR2) were measured by immunofluorescence, co-immunoprecipitation and proximity ligation assays. Anti-thrombotic activity of D39 in vivo was evaluated with a model of inferior vena cava ligation injury in mice.

Key Results: D39 inhibited tissue factor expression and procoagulant activities in HUVECs and decreased thrombus weight in inferior vena cava-ligated mice dose-dependently. Serial affinity chromatography and molecular docking analysis suggested that D39 bound to NMMHC IIA. In HEK293T cells, D39 inhibited tissue factor expression evoked by NMMHC IIA overexpression. This effect was blocked by NMMHC IIA knockdown in HUVECs. D39 inhibited dissociation of NMMHC IIA from TNFR2, which subsequently modulated the Akt/GSK3β-NF-κB signalling pathways.

Conclusions And Implications: D39 inhibited tissue factor expression and thrombus formation by modulating the Akt/GSK3β and NF-κB signalling pathways through NMMHC IIA. We identified a new natural product that targeted NMMHC IIA, as a potential treatment for thrombotic disorders and other vasculopathies.

Citing Articles

Potential mechanistic linkages of Naoluotong granules on the remission of atherosclerosis by multidimensional analysis.

Zhu S, Liu Y, Bu W, Liu Y, Chen W, Liu F Heliyon. 2024; 10(19):e37957.

PMID: 39386883 PMC: 11462233. DOI: 10.1016/j.heliyon.2024.e37957.


Design, Synthesis, and Antirheumatoid Arthritis Mechanism of TLR4 Inhibitors.

Zhou S, Xue W, Tan J ACS Omega. 2024; 9(34):36232-36241.

PMID: 39220494 PMC: 11359639. DOI: 10.1021/acsomega.4c02344.


Expression of nonmuscle myosin IIC is regulated by non-canonical binding activity of miRNAs.

Banerjee K, Saha S, Das S, Ghosal S, Ghosh I, Basu A iScience. 2023; 26(12):108384.

PMID: 38047082 PMC: 10690570. DOI: 10.1016/j.isci.2023.108384.


SENP2-mediated SERCA2a deSUMOylation increases calcium overload in cardiomyocytes to aggravate myocardial ischemia/reperfusion injury.

Luo Y, Zhou S, Xu T, Wu W, Shang P, Wang S Chin Med J (Engl). 2023; 136(20):2496-2507.

PMID: 37462038 PMC: 10586866. DOI: 10.1097/CM9.0000000000002757.


Shenxiong glucose injection inhibits oxidative stress and apoptosis to ameliorate isoproterenol-induced myocardial ischemia in rats and improve the function of HUVECs exposed to CoCl.

Wu Z, Chen S, Lu D, Xue W, Sun J, Zheng L Front Pharmacol. 2023; 13:931811.

PMID: 36686658 PMC: 9849394. DOI: 10.3389/fphar.2022.931811.


References
1.
Guha M, Mackman N . The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002; 277(35):32124-32. DOI: 10.1074/jbc.M203298200. View

2.
Alexander S, Fabbro D, Kelly E, Marrion N, Peters J, Benson H . The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol. 2015; 172(24):5979-6023. PMC: 4718208. DOI: 10.1111/bph.13353. View

3.
Zhai K, Zheng J, Tang Y, Li F, Lv Y, Zhang Y . The saponin D39 blocks dissociation of non-muscular myosin heavy chain IIA from TNF receptor 2, suppressing tissue factor expression and venous thrombosis. Br J Pharmacol. 2017; 174(17):2818-2831. PMC: 5554322. DOI: 10.1111/bph.13885. View

4.
Chen H, Zhao J, Zhang G, Kou J, Yu B . An optimized micro-assay of myosin II ATPase activity based on the molybdenum blue method and its application in screening natural product inhibitors. Chin J Nat Med. 2016; 14(6):421-6. DOI: 10.1016/S1875-5364(16)30038-3. View

5.
Chandrasekharan U, Dechert L, Davidson U, Waitkus M, Mavrakis L, Lyons K . Release of nonmuscle myosin II from the cytosolic domain of tumor necrosis factor receptor 2 is required for target gene expression. Sci Signal. 2013; 6(284):ra60. PMC: 3837481. DOI: 10.1126/scisignal.2003743. View